Value of transabdominal ultrasonography for diagnosing functional constipation in children: a systematic review and meta-analysis

Duc Long Tran, MD^{1,2}, Phu Nguyen Trong Tran, MD^{1,2}, Paweena Susantitaphong, MD, PhD^{3,4}, Phichayut Phinyo, MD⁵, Palittiya Sintusek, MD, PhD⁶

¹Clinical Sciences Program, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; ²Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam; ³Division of Nephrology, Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, The Thai Red Cross Society, Bangkok, Thailand; ⁴Center of Excellence for Metabolic Bone Disease in CKD Patients, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; ⁵Center for Clinical Epidemiology and Clinical Statistics, Department of Family Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; ⁶Center of Excellence in Thai Pediatric Gastroenterology, Hepatology and Immunology (TPGHAI), Division of Gastroenterology, Department of Pediatrics, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand

Transabdominal ultrasonography is increasingly used as a novel modality for detecting pediatric functional constipation (FC). This systematic review and metaanalysis aimed to assess the diagnostic parameters of FC including rectal diameter (RD) and anterior rectal wall thickness. A systematic search was conducted of the Ovid MEDLINE, Embase, Scopus, and PubMed databases through September 29, 2023, to identify studies comparing RD and anterior wall thickness using transabdominal ultrasonography in children with versus without FC. Metaanalyses were performed using random-effects models to calculate the weighted mean differences (MDs) in RD and anterior wall thickness. Comprehensive Meta-Analysis ver. 3, R, and Review Manager ver. 5.4.1 software were used to assess the optimal cutoff, sensitivity, specificity, and area under the curve (AUC). Fourteen studies involving 1,255 children (mean age, 6.21±2.3 years) were included. The mean RD was significantly larger in constipated children versus controls (MD, 10.35 mm; 95% confidence interval [CI], 6.97-13.74; P<0.001; I²=94%). A meta-regression showed no significant effects of age, weight, or height on RD. An optimal RD cutoff point of 31 mm was suggested by a pooled analysis with an AUC of 0.86 (95% CI, 0.8-0.91; P<0.001), sensitivity of 0.75 (95% CI, 0.59-0.86), and specificity of 0.84 (95% CI, 0.68-0.93). The mean anterior rectal wall thickness was greater among constipated children than among controls (MD, 0.44; 95% CI, -0.26 to 1.13; P=0.22), but this difference was not statistically significant. RD measured using transabdominal ultrasonography with a cutoff point of 31 mm exhibited good diagnostic accuracy for diagnosing FC in children.

Key words: Child, Functional constipation, Ultrasonography, Meta-analysis, Rectal diameter

Key message

- Functional constipation in children places great burden on their physical and psychological well-being; hence, its prompt diagnosis is needed.
- A larger rectal diameter in children with functional constipation was proposed as a noninvasive diagnostic parameter.
- This meta-analysis highlights the clinical usefulness and optimal cutoff value of rectal diameter measured using transabdominal ultrasonography as a diagnostic criterion for functional constipation in children

Introduction


Functional constipation (FC) is a common functional gastrointestinal disorder in pediatric patients, accounting for up to 25% of visits to pediatric gastroenterologists¹⁾ with a global prevalence of 14.4% among children.²⁾ This condition significantly increases healthcare costs^{3,4)} and adversely impacts children's quality of life and psychological well-being.⁵⁾ Thus, the early diagnosis and timely management of FC in children are essential.

The Rome criteria have long been the primary diagnostic tools for FC in children. These criteria incorporate an assessment of medical history, such as infrequent bowel movements, withholding behavior, painful defecation, large stools, soiling among toilet-trained children, and

Received: 25 June 2024, Revised: 19 August 2024, Accepted: 30 August 2024

Corresponding author: Palittiya Sintusek, MD, PhD. Center of Excellence in Thai Pediatric Gastroenterology, Hepatology and Immunology (TPGHAI), Division of Gastroenterology, Department of Pediatrics, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok 10330, Thailand Email: palittiya.s@chula.ac.th, https://orcid.org/0000-0002-2576-9209

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2025 by The Korean Pediatric Society



Graphical abstract. AUC, area under the curve; CI, confidence interval.

history of stool blockages, along with a clinical examination, particularly noting the presence of large stools in the rectum.^{6,7)} Clinical assessments typically involve an abdominal examination and/or digital rectal examination (DRE) to detect a rectal fecal mass, which is found in approximately 30%–75% of diagnosed cases of FC.^{1,8,9)}

However, DRE is often avoided by physicians, especially in young children, because of its discomfort and invasiveness, which can lead to fear of defecation and complicated constipation treatment.¹⁰⁾ The absence of information about large stools in the rectum can complicate FC diagnostics. Additionally, other diagnostic tools such as abdominal radiography have low accuracy for differentiating fecal load from fecal impaction.¹¹⁾

Transabdominal ultrasonography recently emerged as a promising alternative for assessing fecal impaction or large stools in the rectum since it is easy to perform, noninvasive, and free from radiation exposure, making it well accepted by children and their parents.¹²⁻¹⁵ Additionally, systematic reviews indicated that larger rectal diameters (RDs) measured via transabdominal ultrasonography strongly correlate with the presence of large stools in the rectum as detected by DRE, suggesting its possible replacement.^{12-14,16,17}

In cases of withholding behavior, the accumulation of fecal matter in the rectum gradually causes rectal enlargement. Thus, measuring RD as an additional parameter for diagnosing FC in children represents a novel approach.^{18,19} However, the lack of standardized cutoff points for RD across studies poses a challenge for clinical application. Other proposed parameters from transabdominal ultrasonography for diagnosing FC include anterior rectal wall diameter, large fecal content in the rectum, and rectopelvic ratio. Therefore, this systematic review and meta-analysis aimed to establish a reference for normal RD values in children and set criteria for dilation in cases of constipation. The values of other parameters were evaluated using transabdominal ultrasonography to diagnose FC in children.

Methods

This systematic review, meta-analysis, and meta-regression followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines (Supplementary material 1). The protocol for this review was registered with PROSPERO (CRD42023430645) on June 9, 2023.

1. Literature review and search strategy

A systematic literature search was conducted of the Ovid MEDLINE, Embase, Scopus, and PubMed databases to identify publications comparing the RD and anterior wall thickness measured using transabdominal ultrasonography in children with versus without FC from inception until September 29, 2023. The search used terms encompassed the following 3 concepts: (1) children and pediatrics, (2) constipation, and (3) ultrasonography. MeSH (medical subject headings) database terms were used for the search (Supplementary material 2).

2. Eligibility criteria

This review included cross-sectional, case-control, and cohort studies comparing the parameters measured by abdominal ultrasonography (index test) in children under 18 years of age with or without a clinical diagnosis of FC (study domain) using modified Rome criteria and Rome criteria as the reference test. Studies are required to report data on parameters such as RD and anterior wall thickness measured using transabdominal ultrasonography. Only full-text articles were considered, while case reports, review articles, animal studies, and studies involving patients with organic causes of constipation were excluded.

3. Study screening and data abstraction

All search results were uploaded to COVIDENCE to manage duplicates. Prior to the data abstraction, citations were screened in 3 stages: (1) title and abstract screening, (2) retrieval and examination of the full text, and (3) full-text review. Step (1) was independently conducted by 2 investigators (DLT and PNTT) using COVIDENCE's voting function; conflicts were resolved by a third author (P Sintusek). The reasons for study exclusion are documented (Supplementary material 3). A standardized form was used to extract the data, which included study details such as author, year of publication, country, study design, population characteristics, method of parameters measured by abdominal ultrasonography, and outcomes (e.g., mean age, height, weight, RD, anterior rectal wall thickness, cutoff points, true positives, false positives, true negatives, and false negatives). Parallel extractions by the 2 investigators were cross-verified, and additional information was requested from the authors via email when necessary.

4. Risk of bias evaluation

Two authors (DLT and P Sintusek) independently assessed each study's risk of bias (RoB) using the Quality Assessement of Diagnostic Accuracy Studies (QUADAS-2) with 4 domains: patient selection, index test, reference standard, and flow/timing.²⁰⁾ The first 3 domains were used to address the applicability concerns. Each domain was rated as low, unclear, or high risk. A study received a "low risk of bias" classification if all domains were rated "low" for both bias and applicability. Studies were deemed "high risk" if any domain was rated as "unclear."

5. Statistical analysis

Comprehensive Meta-Analysis software version 3 and Review Manager 5.4.1 (Cochrane Collaboration, London, UK) were used to conduct the meta-analysis. We used random-effects models in conjunction with the inversevariance formula for continuous variables irrespective of heterogeneity. Three indicators—mean difference (MD), standard deviation (SD), and 95% confidence interval (CI)— were used to express the difference estimates. Heterogeneity was assessed using I² statistics and categorized as insignificant (0%–25%), low (26%–50%), moderate (51%–75%), or high (>75%). Statistical significance was set at 2-tailed values of *P*=0.05. Data originally presented as median and interquartile range were converted to mean and SD formats using the method described by Wan et al.²¹)

Comprehensive Meta-Analysis version 3 software was used to conduct a meta-regression to explore potential moderators influencing the effect size of RD, including mean age, mean height, and mean weight. A significant relationship between moderators and effect size was determined using Q model statistics with a value of P< 0.05, indicating intergroup variation in RD according to the slope values of the significant moderators (*z* statistics, P<0.05).

We followed the method of Steinhauser et al.²²⁾ using R package diagmeta in Rstudio for Mac OS to ascertain the ideal RD cutoff point and its corresponding sensitivity and specificity for detecting FC. Diagnostic accuracy was evaluated using the summary receiver operating characteristic (SROC) curve. An area under the curve (AUC) of <0.9 suggested very good performance, 0.8–0.9 suggested good performance, 0.7–0.8 suggested fair performance, and 0.6–0.7 suggested poor performance.²³⁾ CI for AUC of SROC was conducted according to the Noma et al.²⁴⁾




Fig. 1. Flow diagram of citation selection process.

method using R package dmetatool in Rstudio for Mac OS.

Results

1. Characteristics of included studies

Using this search strategy, 3,479 potentially eligible articles were identified. After excluding 1,253 duplicates using management software, a title and abstract screening was performed, resulting in the removal of 2,198 irrelevant studies (Fig. 1). Subsequently, 28 articles were subjected to full-text assessment. During this step, 7 articles that lacked a control group, 3 conference reports, 2 articles with incorrect outcomes, 1 abstract-only article, and 1 article including duplicate data were excluded

Table 1. Characteristics of included studies

(Supplementary material 3). Ultimately, 14 articles were included in the analyses, including 2 cohort studies,^{14,25)} 3 cross-sectional studies,²⁶⁻²⁸⁾ and 9 case-control studies. ^{12,13,17,29-34)} The mean age of children with FC was 6.21±2.3 years. The characteristics of the included studies are listed in Table 1.

The application of QUADAS-2 to each study revealed that 9 articles had a high RoB and 5 articles had an unclear RoB. The domain ratings for each study are presented in Supplementary material 4.

2. Outcomes assessment

1) Rectal diameter

Fourteen studies (n=1,257) reported the RD measured

Study Country		C L L L		Population	Age,	Patients	Rectal diameter	Blind	Rectal diameter (mm)		Risk of
	Country	Study design	Case	Control	range	included in analysis	measurement	technique	Case	Control	bias
Klijn et al. 2004 ²⁹⁾	Netherlands	Case-control study	Modified Rome criteria	Children with urolo- gical children	5-13 Yr	49	The probe was placed on the abdominal skin 2 cm above the sym- physis and positioned at an approximate 15° angle downward from the transverse plane.	Not mentioned	49.0±10.1	21.0±6.4	High
Singh et al. 2005 ¹⁷⁾	UK	Case-control study	Modified Rome criteria	Healthy children	0.3–16.4 Yr	177	Modified Klijn et al. technique	Not mentioned	34(21–70)	24(13–42)	Unclea
Bijoś et al. 2007 ³⁴⁾	Poland	Case-control study	RomeII	Healthy children	1.6–17.9 Yr	225	Klijn et al. technique	Not mentioned	43.10±9.68	31.80±8.24	Unclear
Joensson et al. 2008 ¹³⁾	Denmark	Case-control study	Rome III	Healthy children	4–12 Yr	49	Klijn et al. technique	Not mentioned	42.1±15.4	21.4±6.0	Unclear
Karaman et al.2010 ¹²⁾	Turkey	Case-control study	Rome III	Healthy children	0–18 Yr	66	RD was measured at the level of the uterine corpus-cervix junction or the prostate base	Yes	30.2±10.4	1.98±0.64	High
Burgers et al. 2013 ¹⁶⁾	Netherlands	Cross-sectional study	Rome III	Children with urolo- gical problems	4–17 Yr	72	Klijn et al. technique	Yes	28 (21–38)	24(20–29)	High
Modin et al. 2015 ³³⁾	Denmark	Case-control study	Rome III	Healthy children	4–12 Yr	28	Klijn et al. technique	Not mentioned	22.6±5.2	19.6±4.6	Unclear
Hatori et al. 2017 ²⁷⁾	Japan	Cross-sectional study	RomeIII	Children performed abdominal ultraso- nography caused by other reasons	0–15 Yr	100	Klijn et al. technique	Not mentioned	27.7±1.7	23.6±3.5	High
Doniger et al.2018 ¹⁴⁾	USA	Cohort study	Rome III	Children with abdo- minal pain	4–18 Yr	50	Klijn et al. technique	Yes	43.0±13.5	28.5±11.6	High
Momeni et al. 2019 ³²⁾	Iran	Case-control study	Rome III	Children performed abdominal ultraso- nography caused by other reasons	1.5–14 Yr	76	RD was measured at the level of the rectal ampulla	Not mentioned	31.70±9.63	19.8±4.3	High
De Abreu et al. 2020 ²⁶⁾	Brazil	Cross-sectional study	Rome IV	Children with urolo- gical problems	4–17 Yr	107	Klijn et al. technique	Not mentioned	30±8	29±10	High
Pop et al. 2021 ³⁰⁾	Romania	Case-control study	Rome III or Rome IV	Healthy children	0–18 Yr	65	Klijn et al. technique	Not mentioned	35.9±14.1	24.2±7.1	Unclear
Hamdy et al. 2023 ³¹⁾	Egypt	Case-control study	Rome IV	Children performed abdominal ultraso- nography caused by other reasons	2–11 Yr	100	Klijn et al. technique	Not mentioned	35.5 (32.0–40.0)	23 (18–25)	High
Gatzinsky et al. 2023 ²⁵⁾	Sweden	Cohort study	RomeIII	Healthy infants	1–12 Mo	91	Klijn et al. technique	Not mentioned	18.50±0.59	17.8±4.7	High


Values are presented as median (interquartile range) or mean±standard deviation.

A. Forest-plot analysis for rectal diameter in children

	Constipation			Control			Mean Difference			Mean Difference		
Study or Subgroup	or Subgroup Mean SD Total Mean SD Total Weight IV, Ran		IV, Random, 95% CI	Year	IV, Random, 95% CI							
Klijn 2004	49	10.1	23	21	6.4	26	6.8%	28.00 [23.19, 32.81]				
Singh 2005	35.3	9.9	95	24.4	6	82	7.6%	10.90 [8.52, 13.28]	2005	-		
Bijos 2007	43.1	9.7	120	31.8	8.2	105	7.6%	11.30 [8.96, 13.64]		-		
Joensson 2008	39.6	8.2	27	21.4	6	22	7.1%	18.20 [14.22, 22.18]				
Karaman 2010	34.2	10.4	35	21.2	6.5	31	7.1%	13.00 [8.86, 17.14]				
Burgers 2013	29.1	13.2	31	24.4	6.9	41	6.7%	4.70 [-0.40, 9.80]				
Modin 2015	22.6	5.2	14	19.6	4.6	14	7.3%	3.00 [-0.64, 6.64]		-		
Hatori 2017	27.7	1.7	80	23.6	3.5	20	7.8%	4.10 [2.52, 5.68]		-		
Doniger 2018	43	13.5	32	28.5	11.6	18	5.9%	14.50 [7.39, 21.61]				
Momeni 2019	31.7	9.6	30	19.9	4.4	46	7.2%	11.80 [8.14, 15.46]				
Abreu 2020	30	8	72	29	10	35	7.2%	1.00 [-2.79, 4.79]		+		
Pop 2021	35.9	14.1	34	24.2	7.1	31	6.6%	11.70 [6.34, 17.06]				
Gatzinsky 2023	18.5	5.9	13	17.8	4.7	78	7.3%	0.70 [-2.67, 4.07]		+		
Hamdy 2023	35.9	6.1	50	21.9	5.3	50	7.7%	14.00 [11.76, 16.24]		-		
Total (95% CI)			656			599	100.0%	10.35 [6.97, 13.74]		•		
Heterogeneity: Tau ² =	= 37.74:	Chi ² =	205.5	3. df =	13 (P	< 0.00	001): I ² =	= 94%	<u> </u>			
Test for overall effect					6				-50	-25 Ó 25 50 Favours [Control] Favours [Constipation]		

B. Forest-plot subgroup analysis for rectal diameter

B1. Continen	t	•		-					
	Cor	nstipati			ontro			Mean Difference	Mean Difference
Study or Subgroup 2.1.1 American	Mean	SD.	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Doniger 2018	43	13.5	32	28.5	11.6	18	5.9%	14.50 [7.39, 21.61]	
Abreu 2020	30	8	72 104	29	10	35 53	7.2% 13.1%	1.00 [-2.79, 4.79] 7.40 [-5.81, 20.61]	+-
Subtotal (95% CI) Heterogeneity: Tau ²	= 82.67	· Chi ² =			1 (P =				
Test for overall effect					. (.	01001)			
2.1.2 Asia									
Hatori 2017	27.7		80		3.5	20	7.8%	4.10 [2.52, 5.68]	-
Momeni 2019 Subtotal (95% CI)	31.7	9.6	30 110		4.4	46 66	7.2% 15.0%	11.80 [8.14, 15.46] 7.77 [0.23, 15.30]	<u> </u>
Heterogeneity: Tau ²	= 27.57	; Chi ² =			1 (P =				-
Test for overall effect	t: Z = 2.	02 (P =	= 0.04)						
2.1.3 African									
Hamdy 2023 Subtotal (95% CI)	35.9	6.1	50 50	21.9	5.3	50 50	7.7% 7.7%	14.00 [11.76, 16.24] 14.00 [11.76, 16.24]	T
Heterogeneity: Not a	pplicabl	р	50			50	1.176	14.00 [11.76, 16.24]	•
Test for overall effect	t: Z = 1	2.25 (P	< 0.00	0001)					
2.1.4 Europe									
Klijn 2004		10.1	23	21	6.4	26		28.00 [23.19, 32.81]	
Singh 2005	35.3		95 120	24.4	6	82 105	7.6%	10.90 [8.52, 13.28]	-
Bijos 2007 Joensson 2008	43.1 39.6		27	31.8 21.4	8.2 6	22	7.6%	11.30 [8.96, 13.64] 18.20 [14.22, 22.18]	· · · · · · · · · · · · · · · · · · ·
Karaman 2010	34.2	10.4	35	21.2	6.5	31	7.1%	13.00 [8.86, 17.14]	
Burgers 2013		13.2	31	24.4	6.9	41	6.7%	4.70 [-0.40, 9.80]	-
Modin 2015 Pop 2021	22.6 35.9		14 34	19.6 24.2	4.6 7.1	14 31	7.3% 6.6%	3.00 [-0.64, 6.64] 11.70 [6.34, 17.06]	
Gatzinsky 2023	18.5		13		4.8	78	7.3%	0.70 [-2.68, 4.08]	+ -
Subtotal (95% CI) Heterogeneity: Tau ²	- 45 90	chi? -	392	oz df -	0 /D	430	64.2%	11.20 [6.58, 15.82]	•
Test for overall effect					· 0 (F ·	. 0.000	(01), 1 =	33%	
Total (95% CI)			656			599	100.0%	10.35 [6.97, 13.74]	
Heterogeneity: Tau ²	= 37.73	: Chi ² =		44. df =	13 (P				-50 -25 - 0 - 25 - 50
Test for overall effect	t: Z = 5.	99 (P <	< 0.000	001)					-50 -25 0 2'5 50' Favours [Control] Favours [Constipation]
Test for subgroup dif	ference	s: Chi ^e	= 3.89	, df = 3	(P =)).27), ľ	= 22.9%		
B2. Condition						oup			
	Con	stipatio	on	C	ontrol	•		Mean Difference	Mean Difference
Study or Subgroup	Con Mean	stipatio		C	ontrol	•	Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.2.1 Healthy childre	Con Mean n	stipatio SD	on Total	Co Mean	ontrol SD	- Total		IV, Random, 95% CI	
Study or Subgroup	Con Mean	stipatio	on	C	ontrol	•	Weight 7.6% 7.6%		
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008	Con Mean 35.3 43.1 39.6	stipatio SD 9.9 9.7 8.2	0n Total 95 120 27	24.4 31.8 21.4	6 8.2 6	Total 82 105 22	7.6% 7.6% 7.1%	IV, Random, 95% CI 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 18.20 [14.22, 22.18]	
Study or Subgroup 2.2.1 Healthy childres Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010	Con Mean 35.3 43.1 39.6 34.2	9.9 9.7 8.2 10.4	0n Total 95 120 27 35	24.4 31.8 21.4 21.2	6 8.2 6 6.5	Total 82 105 22 31	7.6% 7.6% 7.1% 7.1%	IV, Random, 95% Cl 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [8.86, 17.14]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015	Con Mean 35.3 43.1 39.6 34.2 22.6	9.9 9.7 8.2 10.4 5.2	0n Total 95 120 27 35 14	24.4 31.8 21.4 21.2 19.6	6 8.2 6 6.5 4.6	Total 82 105 22 31 14	7.6% 7.6% 7.1% 7.1% 7.3%	IV, Random, 95% CI 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [8.86, 17.14] 3.00 [-0.64, 6.64]	
Study or Subgroup 2.2.1 Healthy childres Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021	Con Mean 35.3 43.1 39.6 34.2 22.6 35.9	9.9 9.7 8.2 10.4 5.2 14.1	95 120 27 35 14 34	24.4 31.8 21.4 21.2 19.6 24.2	6 8.2 6 6.5 4.6 7.1	Total 82 105 22 31 14 31	7.6% 7.6% 7.1% 7.1% 7.3% 6.6%	IV, Random, 95% CI 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [8.86, 17.14] 3.00 [-0.64, 6.64] 11.70 [6.34, 17.06]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015	Con Mean 35.3 43.1 39.6 34.2 22.6	9.9 9.7 8.2 10.4 5.2	0n Total 95 120 27 35 14	24.4 31.8 21.4 21.2 19.6	6 8.2 6 6.5 4.6	Total 82 105 22 31 14	7.6% 7.6% 7.1% 7.1% 7.3% 6.6% 7.3%	IV, Random, 95% CI 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [8.86, 17.14] 3.00 [-0.64, 6.64]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% CI) Heterogeneiny: Tau ² =	Con Mean 35.3 43.1 39.6 34.2 22.6 35.9 18.5 27.19;	9.9 9.7 8.2 10.4 5.2 14.1 5.9 Chi ² =	on Total 95 120 27 35 14 34 13 338 63.66	24.4 31.8 21.4 21.2 19.6 24.2 17.8 , df = 6	6 8.2 6 6.5 4.6 7.1 4.7	Total 82 105 22 31 14 31 78 363	7.6% 7.6% 7.1% 7.1% 7.3% 6.6% 7.3% 50.7%	IV, Random, 95% CI 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [-0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [-2.67, 4.07] 9.76 [5.66, 13.87]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% CI)	Con Mean 35.3 43.1 39.6 34.2 22.6 35.9 18.5 27.19;	9.9 9.7 8.2 10.4 5.2 14.1 5.9 Chi ² =	on Total 95 120 27 35 14 34 13 338 63.66	24.4 31.8 21.4 21.2 19.6 24.2 17.8 , df = 6	6 8.2 6 6.5 4.6 7.1 4.7	Total 82 105 22 31 14 31 78 363	7.6% 7.6% 7.1% 7.1% 7.3% 6.6% 7.3% 50.7%	IV, Random, 95% CI 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [-0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [-2.67, 4.07] 9.76 [5.66, 13.87]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzińsky 2023 Subtotal (95% CI) Heterogeneiky: Tau ² = Test for overall effect:	Con Mean 35.3 43.1 39.6 34.2 22.6 35.9 18.5 227.19: Z = 4.6	9.9 9.7 8.2 10.4 5.2 14.1 5.9 Chi ² = 66 (P <	95 120 27 35 14 34 13 338 63.66 0.000	24.4 31.8 21.4 21.2 19.6 24.2 17.8 , df = 6	6 8.2 6 6.5 4.6 7.1 4.7	Total 82 105 22 31 14 31 78 363	7.6% 7.6% 7.1% 7.1% 7.3% 6.6% 7.3% 50.7%	IV, Random, 95% CI 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [-0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [-2.67, 4.07] 9.76 [5.66, 13.87]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% CI) Heterogeneiny: Tau ² =	Con Mean 35.3 43.1 39.6 34.2 22.6 35.9 18.5 227.19; Z = 4.6 urologic	9.9 9.7 8.2 10.4 5.2 14.1 5.9 Chi ² = 66 (P <	95 120 27 35 14 34 13 338 63.66 0.000	24.4 31.8 21.4 21.2 19.6 24.2 17.8 , df = 6	6 8.2 6 6.5 4.6 7.1 4.7	Total 82 105 22 31 14 31 78 363	7.6% 7.6% 7.1% 7.1% 7.3% 6.6% 7.3% 50.7% 1); I ² = 9:	IV, Random, 95% CI 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [-0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [-2.67, 4.07] 9.76 [5.66, 13.87]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% Cl) Heterogeneiky: Tau ² Test for overall effect: 2.2.2. Children with u	Con Mean 35.3 43.1 39.6 34.2 22.6 35.9 18.5 2 27.19; Z = 4.6 urologic 49	9.9 9.7 8.2 10.4 5.2 14.1 5.9 Chi ² = 56 (P <	95 120 27 35 14 34 13 338 63.66 0.000 blems	Co Mean 24.4 31.8 21.4 21.2 19.6 24.2 17.8 , df = 6 01)	6 8.2 6.5 4.6 7.1 4.7 6 (P <	Total 82 105 22 31 14 31 78 363 0.00000	7.6% 7.6% 7.1% 7.1% 7.3% 6.6% 7.3% 50.7% 1); I ² = 9:	IV, Random, 95% Cl 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 13.00 [8.86, 17.14] 13.00 [8.86, 17.14] 13.00 [6.34, 17.06] 0.70 [7.267, 4.07] 9.76 [5.66, 13.87] 1%	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% CI) Heterogeneiky: Tau ² = Test for overall effect: 2.2.2. Children with ta Kijin 2004 Burgers 2013 Abreu 2020	Con Mean 35.3 43.1 39.6 34.2 22.6 35.9 18.5 2 27.19; Z = 4.6 urologic 49	stipatic SD 9.9 9.7 8.2 10.4 5.2 14.1 5.9 Chi ² = 56 (P <	on Total 95 120 27 35 14 34 13 338 63.66 0.000 olems 23 31 72	Co Mean 24.4 31.8 21.4 21.2 19.6 24.2 17.8 , df = 6 01) 21	6 8.2 6 6.5 4.6 7.1 4.7 6 (P < 0 6.4	Total 82 105 22 31 14 31 78 363 0.00000 26 41 35	7.6% 7.6% 7.1% 7.3% 6.6% 7.3% 50.7% 1); $l^2 = 9$: 6.8% 6.7% 7.2%	IV, Random, 95% Cl 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 13.00 [8.86, 17.14] 3.00 [-0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [-2.67, 4.07] 9.76 [5.66, 13.87] 3.00 28.00 [23.19, 32.81] 4.70 [-0.40, 9.80]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% Cl) Heterogeneiby: Tau ² = Test for overall effect: 2.2.2. Children with u Klijn 2004 Burgers 2013 Abreu 2020 Subtotal (95% Cl)	Con Mean 35.3 43.1 39.6 34.2 22.6 35.9 18.5 227.19; Z = 4.6 urologic 49 29.1 30	stipatie SD 9.9 9.7 8.2 10.4 5.2 14.1 5.9 Chi ² = 56 (P < chi ² = 56 (P < al prob 10.1 13.2 8	on Total 95 120 27 35 14 34 13 338 63.66 0.000 0lems 23 31 72 126	Co Mean 24.4 31.8 21.4 21.2 19.6 24.2 17.8 , df = 6 01) 21 24.4 29	6 8.2 6 6.5 4.6 7.1 4.7 6 (P < 1 6.4 6.9 10	Total 82 105 22 31 14 31 78 363 0.00000 26 41 35 102	7.6% 7.6% 7.1% 7.3% 6.6% 7.3% 50.7% 1); I ² = 9: 6.8% 6.7% 7.2% 20.7%	IV, Random, 95% Cl 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 13.00 [8.86, 17.14] 3.00 [-0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [-2.67, 4.07] 9.76 [5.66, 13.87] 1% 28.00 [23.19, 32.81] 4.70 [-0.40, 9.80] 1.00 [-2.79, 4.79]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 2.2.2 Children with a Kiljn 2004 Burgers 2013 Abreu 2020 Subtotal (95% CI) Heterogeneity: Tau ² =	Con Mean 35.3 43.1 39.6 34.2 22.6 35.9 18.5 22.6 35.9 18.5 22.19; Z = 4.6 49 29.1 30 29.1 30	stipation 9.9 9.7 8.2 10.4 5.2 14.1 5.9 (Chi ² = 56 (P < chi ² = 10.1 13.2 8; Chi ² =	95 120 27 35 14 13 338 63.66 0.000 0lems 23 31 72 126 = 79.6	Co Mean 24.4 31.8 21.4 21.2 19.6 24.2 17.8 , df = 6 01) 21 24.4 29	6 8.2 6 6.5 4.6 7.1 4.7 6 (P < 1 6.4 6.9 10	Total 82 105 22 31 14 31 78 363 0.00000 26 41 35 102	7.6% 7.6% 7.1% 7.3% 6.6% 7.3% 50.7% 1); I ² = 9: 6.8% 6.7% 7.2% 20.7%	IV, Random, 95% Cl 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 13.00 [8.86, 17.14] 3.00 [-0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [-2.67, 4.07] 9.76 [5.66, 13.87] 1% 28.00 [23.19, 32.81] 4.70 [-0.40, 9.80] 1.00 [-2.79, 4.79]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.2.2 Children with a Kiljn 2004 Burgers 2013 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect:	Con Mean 35.3 43.1 39.6 34.2 22.6 35.9 18.5 227.19; Z = 4.6 urologic 29.1 30 29.1 30 29.1	stipati SD 9.9 9.7 8.2 10.4 5.2 14.1 5.9 5.2 14.1 5.9 Chi ² = 66 66 (P <	on Total 95 120 277 35 14 34 338 63.66 0.0000 blems 23 31 72 126 = 79.6 0.18)	Co Mean 24.4 31.8 21.4 21.2 19.6 24.2 17.8 , df = 6 01) 21 24.4 29	6 8.2 6 6.5 4.6 7.1 4.7 6 (P < 1 6.4 6.9 10	Total 82 105 22 31 14 31 78 363 0.00000 26 41 35 102	7.6% 7.6% 7.1% 7.3% 6.6% 7.3% 50.7% 1); I ² = 9: 6.8% 6.7% 7.2% 20.7%	IV, Random, 95% Cl 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 13.00 [8.86, 17.14] 3.00 [-0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [-2.67, 4.07] 9.76 [5.66, 13.87] 1% 28.00 [23.19, 32.81] 4.70 [-0.40, 9.80] 1.00 [-2.79, 4.79]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.2.2. Children with to Subtotal (95% CI) Heterogeneity: Tau ² Test for overall effect: 2.2.3. Children with to	Con Mean 35.3 43.1 39.6 34.2 22.6 35.9 18.5 2 2.19; 2 = 4.6 arologic 49 29.1 30 2 208.00 2 2 = 1.5 bother pr	stipatie SD 9.9 9.7 8.2 10.4 5.2 10.4 5.2 14.1 5.9 56 (P <	Second State 95 120 277 35 14 34 338 63.666 0.0000 blems 23 31 72 126 = 79.66 0.18)	Co Mean 24.4 31.8 21.4 21.2 19.6 24.2 17.8 , df = 6 01) 24.4 29 1, df =	6 6 8.2 6 6 8.2 6 6 5 4.6 7.1 4.7 6 (P < 1 6.4 6.9 10 2 (P <	Total 82 105 22 31 14 363 363 363 363 0.0000	7.6% 7.6% 7.1% 7.1% 7.3% 6.6% 7.3% 50.7% 1); I ² = 9: 6.8% 6.7% 20.7% 01); I ² = 9	IV, Random, 95% Cl 10.90 [8.52, 13.28] 11.30 (8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [8.86, 17.14] 3.00 [-0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [-2.67, 4.07] 9.76 [5.66, 13.87] % 28.00 [23.19, 32.81] 4.70 [-0.40, 9.80] 1.00 [-2.79, 4.79] 1.20 (-5.33, 27.74] 7%	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.2.2 Children with a Kiljn 2004 Burgers 2013 Abrea 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.2.3 Children with a Hatori 2017	Con Mean 35.3 39.6 34.2 22.6 35.9 18.5 27.19; Z = 4.6 49 29.1 30 29.1 30 208.00 Z = 1.2 508.00 Z = 1.2 508.00 Z = 1.2 508.00 Z = 1.2 508.00 2,2 508.00 2,2 508.00 2,2 508.00 2,2 508.00 2,2 508.00 2,2 508.00 2,2 508.00 2,2 508.00 2,2 508.00 2,2 508.00 2,2 508.00 2,2 508.00 2,2 508.00 2,2 508.00 2,2 508.00 2,2 508.00 2,2 509.00 3,0 509.00 2,2 500.00 2,2 500.00 2,2 500.00 2,2 500.00 2,2 500.00 2,2 500.00 2,2 500.00 2,2 500.00 2,500.00 3,500.00 2,500.0000000000000000000000000000000000	stipatie SD 9.9 9.7 8.2 10.4 5.2 10.4 5.2 14.1 5.6 (P <	on Total 95 120 27 35 14 34 338 63.66 0.0000 blems 23 72 126 = 79.6 0.18) \$ 80	Co Mean 24.4 31.8 21.4 21.2 17.8 , df = 6 01) 24.2 17.8 , df = 6 24.2 29 1, df = 23.6	6 6 8.2 6 6 8.2 6 6 5 4.6 7.1 4.7 6 6 (P < 0 6.4 6.9 10 2 (P < 0 3.5	Total 82 105 22 31 14 31 78 363 0.0000 226 41 13 5 102 0.0000	7.6% 7.1% 7.1% 7.3% 6.6% 7.3% 50.7% 1); I ² = 9: 6.8% 6.7% 20.7% 20.7%	IV, Random, 95% Cl 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 13.00 [8.86, 17.14] 13.00 [8.86, 17.14] 13.00 [0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [-2.67, 4.07] 9.76 [5.66, 13.87] 1% 28.00 [23.19, 32.81] 4.70 [-0.40, 9.80] 1.00 [-2.79, 4.79] 11.20 [-5.33, 27.74] 7% 4.10 [2.52, 5.68]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% CI) Heterogeneiky: Tau ² = Test for overall effect: 2.2.2 Children with of Kijin 2004 Burgers 2013 Subtotal (95% CI) Heterogeneiky: Tau ² Test for overall effect: 2.2.3 Children with of Hatori 2017 Doniger 2018	Con Mean a 35.3 43.1 39.6 34.2 22.6 35.9 18.5 22.7.19; Z = 4.6 49 29.1 30 29.1 30 20.6 49 29.1 30 20.6 49 29.1 30 20.6 49 29.1 30 20.6 49 20.6 49 20.6 40 20.6 40 20.6 40.7	stipatie SD 9.9 9.7 8.2 10.4 5.2 10.4 5.2 10.4 5.9 6 (P <	Second State 95 120 27 35 14 338 63.66 0.000 blems 23 311 72 126 79.6 0.18) 80 32	Co Mean 24.4 31.8 21.4 21.2 17.8 0 24.2 17.8 0 01) 24.4 29 1, df = 6 01) 21 24.4 29 1, df = 2 23.6 28.5	6 6 8.2 6 6 8.2 6 6 6.5 4.6 6 7.1 4.7 6 (P < 0 6.4 6.9 10 2 (P < 3.5 11.6	Total 82 105 22 31 14 363 0.00000 26 41 35 102 0.0000 20 18	7.6% 7.6% 7.1% 7.1% 7.3% 6.6% 7.3% 50.7% 1); I ² = 9 6.8% 6.7% 7.2% 20.7% 01); I ² = 9	IV. Random, 95% CI 10.90 [8.52, 13.28] 11.30 (8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [8.86, 17.14] 3.00 [-0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [-2.67, 4.07] 9.76 [5.66, 13.87] % 28.00 [23.19, 32.81] 4.70 [-0.40, 9.80] 1.00 [-2.74, 4.79] 1.120 [-5.33, 27.74] 7% 4.10 [2.52, 5.68] 14.50 [7.39, 21.61]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.2.2 Children with cl Kiljn 2004 Burgers 2013 Abreu 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.2.3 Children with cl Heterogeneity: Tau ² = Test for overall effect: 2.2.3 Children with cl Hetaroj 2017 Doniger 2018 Momeni 2019	Con Mean n 35.3 43.1 39.6 34.2 22.6 35.9 18.5 27.19; Z = 4.6 49 29.1 30 29.1 30 2 208.00 Z = 1.3 50 208.00 Z = 1.3 30 50 30 2 3 30 30 30 30 30 30 30 30 30 30 30 30 30	stipatic SD 9.9 9.9 9.7 8.2 10.4 5.2 10.4 5.9 Chi ² = 5.6 10.1 13.2 33 (P = 10.7 13.5 9.6 9.6	on Total 95 120 27 35 14 34 338 63.66 0.0000 blems 23 72 126 = 79.6 0.18) \$ 80	Co Mean 24.4 31.8 21.4 21.2 17.8 , df = 6 01) 24.2 17.8 , df = 6 24.2 29 1, df = 23.6	6 6 8.2 6 6 8.2 6 6 5 4.6 7.1 4.7 6 6 (P < 0 6.4 6.9 10 2 (P < 0 3.5	Total 82 105 22 31 14 31 78 363 0.0000 226 41 13 5 102 0.0000	7.6% 7.1% 7.1% 7.1% 7.3% 6.6% 7.3% 50.7% 1); I ² = 9 6.8% 6.7% 7.3% 20.7% 20.7% 20.7% 20.7%	IV, Random, 95% Cl 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 13.00 [8.86, 17.14] 13.00 [8.86, 17.14] 13.00 [0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [2.47, 4.07] 9.76 [5.66, 13.87] 1% 28.00 [23.19, 32.81] 4.70 [-0.40, 9.80] 1.00 [-2.79, 4.79] 11.20 [-5.33, 27.74] 7% 4.10 [2.52, 5.68] 14.50 [7.39, 21.61] 14.50 [7.39, 21.61]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% CI) Heterogeneiky: Tau ² = Test for overall effect: 2.2.2 Children with of Kijin 2004 Burgers 2013 Subtotal (95% CI) Heterogeneiky: Tau ² Test for overall effect: 2.2.3 Children with of Hatori 2017 Doniger 2018	Con Mean a 35.3 43.1 39.6 34.2 22.6 35.9 18.5 22.7.19; Z = 4.6 49 29.1 30 29.1 30 20.6 49 29.1 30 20.6 49 29.1 30 20.6 49 29.1 30 20.6 49 20.6 49 20.6 40 20.6 40 20.6 40.7	stipatie SD 9.9 9.7 8.2 10.4 5.2 10.4 5.2 10.4 5.9 6 (P <	Second State 95 120 27 35 14 338 63.66 0.000 s 23 31 726 97.6 97.6 98 80 320 30	Co Mean 24.4 31.8 21.4 21.2 17.8 , df = 6 01) 21 24.4 29 1, df = 23.6 28.5 19.9	6 6 8.2 6 6.5 4.6 6.5 4.6 7.1 4.7 6 (P < 1 6.4 6.9 10 2 (P < 1 3.5 11.6 4.4	Total 82 105 22 31 14 363 363 30.00000 26 41 35 102 0.00000 20 18 46	7.6% 7.1% 7.1% 7.1% 7.3% 6.6% 7.3% 50.7% 1); I ² = 9 6.8% 6.7% 7.3% 20.7% 20.7% 20.7% 20.7%	IV. Random, 95% CI 10.90 [8.52, 13.28] 11.30 (8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [8.86, 17.14] 3.00 [-0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [-2.67, 4.07] 9.76 [5.66, 13.87] % 28.00 [23.19, 32.81] 4.70 [-0.40, 9.80] 1.00 [-2.74, 4.79] 1.120 [-5.33, 27.74] 7% 4.10 [2.52, 5.68] 14.50 [7.39, 21.61]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% CI) Heterogeneiky: Tau ² = Test for overall effect: 2.2.2. Children with a Kijin 2004 Burgers 2013 Subtotal (95% CI) Heterogeneiky: Tau ² = Test for overall effect: 2.2.3. Children with a Hatori 2017 Heterogeneiky: Tau ² = Test for overall effect: 2.2.3. Children with a Hatori 2017 Heterogeneiky: Tau ² = Heterogeneiky: Tau ² = Heterogeneiky: Tau ² = Heterogeneiky: Tau ² = Heterogeneiky: Tau ² =	$\begin{tabular}{ c c c c } \hline Con \\ \hline Mean \\ \hline m \\ \hline m \\ \hline m \\ \hline 39.6 \\ 34.2 \\ 22.6 \\ 34.2 \\ 22.6 \\ 34.2 \\ 22.6 \\ 34.2 \\ 22.6 \\ 18.5 \\ 18.5 \\ 22.6 \\ 18.5 \\ 22.6 \\ 18.5 \\ 29.1 \\ 30 \\ 30 \\ 29.1 \\ 30 \\ 30 \\ 29.1 \\ 30 \\ 30 \\ 29.1 \\ 30 \\ 30 \\ 20 \\ 20 \\ 20 \\ 20 \\ 20 \\ 20$	stipatie SD 9.9 9.7 8.2 10.4 5.2 14.1 5.9 5.2 14.1 5.9 Chi ² = 66 (P <	Total 95 120 27 35 14 338 63.66 0.000 blems 23 31 72 120 95 80 32 80 32 30 5 5	Co Mean 24.4 31.8 21.4 21.2 24.2 17.8 , df = 6 01) 24.4 29 1, df = 23.6 28.5 19.9 21.9 21.9 2, 4 24.4 29 1, df = 23.6 28.5 19.9 21.9 2, 4 3, 10 2, 10,	SD 6 8.2 6 8.2 6 6.5 4.6 7.1 4.7 6.4 6.9 10 2 (P <	Total 82 105 22 31 14 31 78 363 30.0000 26 41 35 102 0.0000 20 18 46 50 134	7.6% 7.6% 7.1% 7.1% 7.3% 6.6% 7.3% 50.7% 1); I ² = 9 1); I ² = 9 6.8% 6.7% 20.7% 20.7% 20.7% 20.7% 20.7% 20.7% 20.7% 20.7% 20.7% 28.6%	IV, Random, 95% Cl 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [8.86, 17.14] 3.00 [-0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [-2.67, 4.07] 9.76 [5.66, 13.87] % 28.00 [23.19, 32.81] 4.70 [-0.40, 9.80] 1.00 [-2.79, 4.79] 11.20 [-5.33, 27.74] 17% 4.10 [2.52, 5.68] 14.50 [7.39, 21.61] 13.80 [8.14, 15.46] 14.01 [1.76, 16.24]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.2.2 Children with d Kiljn 2004 Burgers 2013 Abreu 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.2.3 Children with d Hatori 2017 Doniger 2018 Momeni 2019 Hamdy 2023 Subtotal (95% CI)	$\begin{tabular}{ c c c c } \hline Con \\ \hline Mean \\ \hline m \\ \hline m \\ \hline m \\ \hline 39.6 \\ 34.2 \\ 22.6 \\ 34.2 \\ 22.6 \\ 34.2 \\ 22.6 \\ 34.2 \\ 22.6 \\ 18.5 \\ 18.5 \\ 22.6 \\ 18.5 \\ 22.6 \\ 18.5 \\ 29.1 \\ 30 \\ 30 \\ 29.1 \\ 30 \\ 30 \\ 29.1 \\ 30 \\ 30 \\ 29.1 \\ 30 \\ 30 \\ 20 \\ 20 \\ 20 \\ 20 \\ 20 \\ 20$	stipatie SD 9.9 9.7 8.2 10.4 5.2 14.1 5.9 5.2 14.1 5.9 Chi ² = 66 (P <	Total 95 120 27 35 14 338 63.66 0.000 blems 23 31 72 120 95 80 32 80 32 30 5 5	Co Mean 24.4 31.8 21.4 21.2 24.2 17.8 , df = 6 01) 24.4 29 1, df = 23.6 28.5 19.9 21.9 21.9 2, 4 24.4 29 1, df = 23.6 28.5 19.9 21.9 2, 4 3, 10 2, 10,	SD 6 8.2 6 8.2 6 6.5 4.6 7.1 4.7 6.4 6.9 10 2 (P <	Total 82 105 22 31 14 31 78 363 30.0000 26 41 35 102 0.0000 20 18 46 50 134	7.6% 7.6% 7.1% 7.1% 7.3% 6.6% 7.3% 50.7% 1); I ² = 9 1); I ² = 9 6.8% 6.7% 20.7% 20.7% 20.7% 20.7% 20.7% 20.7% 20.7% 20.7% 20.7% 28.6%	IV, Random, 95% Cl 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [8.86, 17.14] 3.00 [-0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [-2.67, 4.07] 9.76 [5.66, 13.87] % 28.00 [23.19, 32.81] 4.70 [-0.40, 9.80] 1.00 [-2.79, 4.79] 11.20 [-5.33, 27.74] 17% 4.10 [2.52, 5.68] 14.50 [7.39, 21.61] 13.80 [8.14, 15.46] 14.01 [1.76, 16.24]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% CI) Heterogeneiky: Tau ² = Test for overall effect: 2.2.2. Children with a Kijin 2004 Burgers 2013 Subtotal (95% CI) Heterogeneiky: Tau ² = Test for overall effect: 2.2.3. Children with a Hatori 2017 Heterogeneiky: Tau ² = Test for overall effect: 2.2.3. Children with a Hatori 2017 Heterogeneiky: Tau ² = Heterogeneiky: Tau ² = Heterogeneiky: Tau ² = Heterogeneiky: Tau ² = Heterogeneiky: Tau ² =	$\begin{tabular}{ c c c c } \hline Con \\ \hline Mean \\ \hline m \\ \hline m \\ \hline 39.6 \\ 34.2 \\ 22.6 \\ 34.2 \\ 22.6 \\ 35.9 \\ 18.5 \\ 18.5 \\ 22.7.19; \\ z & -4.6 \\ 49 \\ 29.1 \\ 30 \\ 29.1 \\ 30 \\ z & -20.80, 01 \\ z & -1.5 \\ 30 \\ z & -1.5 \\ z$	stipatie SD 9.9 9.7 8.2 10.4 5.2 14.1 5.9 5.2 14.1 5.9 Chi ² = 66 (P <	Total 95 120 27 35 14 338 63.66 0.000 blems 23 31 72 120 95 80 32 80 32 30 5 5	Co Mean 24.4 31.8 21.4 21.2 24.2 17.8 , df = 6 01) 24.4 29 1, df = 23.6 28.5 19.9 21.9 21.9 2, 4 24.4 29 1, df = 23.6 28.5 19.9 21.9 2, 4 3, 10 2, 10,	SD 6 8.2 6 8.2 6 6.5 4.6 7.1 4.7 6.4 6.9 10 2 (P <	Total 82 105 222 31 14 363 363 0.00000 266 41 35 102 0.00000 20 18 46 50 134 0.00000	7.6% 7.6% 7.1% 7.1% 7.3% 6.6% 7.3% 50.7% 1); I ² = 9 1); I ² = 9 6.8% 6.7% 20.7% 20.7% 20.7% 20.7% 20.7% 20.7% 20.7% 20.7% 20.7% 28.6%	IV, Random, 95% Cl 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [8.86, 17.14] 3.00 [-0.64, 6.64] 11.70 [6.34, 17.06] 0.70 [-2.67, 4.07] 9.76 [5.66, 13.87] % 28.00 [23.19, 32.81] 4.70 [-0.40, 9.80] 1.00 [-2.79, 4.79] 11.20 [-5.33, 27.74] 17% 4.10 [2.52, 5.68] 14.50 [7.39, 21.61] 13.80 [8.14, 15.46] 14.01 [1.76, 16.24]	
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Catzinsky 2023 Subtotal (95% CI) Heterogeneiky: Tau ² = Test for overall effect: 2.2.2. Children with a Klijn 2004 Burgers 2013 Subtotal (95% CI) Heterogeneiky: Tau ² = Test for overall effect: 2.2.3. Children with a Hatori 2015 Momeni 2019 Hatory 2023 Subtotal (95% CI) Heterogeneiky: Tau ² = Test for overall effect: 2.2.3. Children with a Hatori 2015 Heterogeneiky: Tau ² = Test for overall effect: 2.2.4.1 Heterogeneiky: Tau ² = Test for overall effect: 2.2.5.1 Comparison 2.2.1 Subtotal (95% CI) Heterogeneiky: Tau ² = Test for overall effect:	Con Mean 35.3 39.6 34.2 22.6 35.9 18.5 27.19; Z = 4.6 49 29.1 30 208.00 Z = 1.3 30 208.00 Z = 1.3 30 27.7 43 31.7 35.9 27.7 43 31.7 35.9 27.7 43 31.7 35.9 27.7 43 31.7 35.9 27.7 43 31.7 35.9 27.7 43 31.7 35.9 27.7 43 31.7 35.9 27.7 43 31.7 35.9 27.7 43 31.7 35.9 45.7 35.7 35.7 35.7 35.7 35.7 35.7 35.7 3	stipatie SD 9.9 9.7 8.2 10.4 5.2 14.1 5.9 16.4 5.2 14.1 5.9 16.6 66 (P <	Solution 95 120 27 35 120 27 35 63.66 0.000 blems 23 31 72 126 = 79.6 0.18) \$ 8 0.000 192 58.35 0.000 656	24.4 31.8 21.4 21.2 19.6 21.2 19.6 24.2 19.6 24.2 19.6 24.2 17.8 , df = 6 21.1 21.2 17.8 , df = 3 21.1 24.4 29 1, df = 23.6 21.9 21.9 , df = 3 6) 10	SD 6 8.2 6 8.2 6 7.1 4.7 6.4 6.9 10 2 (P <	Total 82 105 22 31 14 363 363 363 30.00000 200 102 0.00000 200 102 102 0.00000 599	$\begin{array}{c} \textbf{7.6\%}\\ \textbf{7.6\%}\\ \textbf{7.6\%}\\ \textbf{7.1\%}\\ \textbf{7.1\%}\\ \textbf{7.1\%}\\ \textbf{50.7\%}\\ \textbf{50.7\%}\\ \textbf{50.7\%}\\ \textbf{50.7\%}\\ \textbf{50.7\%}\\ \textbf{50.7\%}\\ \textbf{50.7\%}\\ \textbf{7.3\%}\\ \textbf{7.3\%}\\ \textbf{7.3\%}\\ \textbf{7.3\%}\\ \textbf{7.3\%}\\ \textbf{7.3\%}\\ \textbf{7.3\%}\\ \textbf{7.3\%}\\ \textbf{7.3\%}\\ \textbf{7.2\%}\\ \textbf{7.2\%}$	IV, Random, 95% CI 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [8.86, 17.14] 13.00 [6.34, 17.06] 0.70 [2.46, 6.64] 11.70 [6.34, 17.06] 0.70 [2.46, 4.61] 11.70 [6.34, 17.06] 0.70 [2.46, 4.61] 11.70 [1.63, 17.06] % 28.00 [23.19, 32.81] 4.70 [-0.40, 9.80] 1.00 [-2.79, 4.79] 11.20 [-2.52, 5.68] 14.50 [7.39, 21.61] 11.80 [8.14, 15.46] 10.64 [4.61, 17.66] 10.64 [4.61, 17.66] %	IV, Random, 95% CI
Study or Subgroup 2.2.1 Healthy childre Singh 2005 Bijos 2007 Joensson 2008 Karaman 2010 Modin 2015 Pop 2021 Gatzinsky 2023 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2.2.2 Children with to Kijin 2004 Burgers 2013 Subtotal (95% CI) Heterogeneity: Tau ² Test for overall effect: 2.2.3 Children with to Hatori 2017 Doniger 2018 Momeni 2019 Heterogeneity: Tau ² Test for overall effect: 2.2.3 Subtotal (95% CI) Heterogeneity: Tau ² Test for overall effect: Test for overall effect: Total (95% CI)	Con Mean 35.3 43.1 39.6 34.2 22.6 35.9 18.5 27.19; Z = 4.6 49 29.1 30 29.1 30 29.1 30 29.1 30 29.1 30 29.1 30 29.1 30 29.1 30 29.1 30 29.1 30 29.1 30 29.1 30 29.1 30 29.1 30 29.1 30.5 35.9 29.1 30.5 35.9 29.1 30.5 35.9 29.1 30.5 35.9 29.1 30.5 35.9 20.5 20.5 20.5 20.5 20.5 20.5 20.5 20.5	stipatie SD 9.9 9.7 8.2 10.4 5.2 14.1 5.9 Chi ² = 5 (P < all probe 13.2 8 3; Chi ² , 33 (P = 1.7 1.3,5 9.6 6.1 Chi ² = 4 (P < Chi ² = 5 9.6 6.1 Chi ² = 2 9.6 (P < Chi ² = 2 (P < Chi ² = 2 (C	Second State Second State 95 120 27 31 338 63.66 63.66 0.000 0 0 0 23 311 72 120 6 0.018) 95 120 0.018) 32 300 50 192 58.355 0.0000 656 205.55 0.0000	Cro Mean 24.4 31.8 21.4 21.2 17.8 , df = 6 01) 24.2 24.2 17.8 24.2 17.8 24.2 17.8 24.2 17.8 24.2 17.8 24.2 17.8 24.4 29 1, df = 6 24.2 21.4 24.2 17.8 24.2 24.2 17.8 24.4 24.2 17.8 24.4 24.2 17.8 24.2 24.2 24.2 24.2 17.8 24.2 24.4 29 21.9 21.4 24.2 29 21.9 21.4 24.2 29 21.9 2	6 4 6.9 10 2 (P < 0 3.5 11.6 4.4 5.3 3 (P < 1 13 (P < 1 13 (P < 1 13 (P) 13 (Total 82 105 22 31 14 363 30.00000 26 41 35 102 0.00000 20 18 46 50 134 0.00000 599 <<0.0000	7.6% 7.7.8% 7.1% 7.3% 6.6% 5.07% 5.07% 6.7.3% 5.07% 6.7.3% 5.07% 7.3% 20.7% 20	IV, Random, 95% CI 10.90 [8.52, 13.28] 11.30 [8.96, 13.64] 18.20 [14.22, 22.18] 13.00 [8.86, 17.14] 13.00 [6.34, 17.06] 0.70 [2.46, 6.64] 11.70 [6.34, 17.06] 0.70 [2.46, 4.61] 11.70 [6.34, 17.06] 0.70 [2.46, 4.61] 11.70 [1.63, 17.06] % 28.00 [23.19, 32.81] 4.70 [-0.40, 9.80] 1.00 [-2.79, 4.79] 11.20 [-2.52, 5.68] 14.50 [7.39, 21.61] 11.80 [8.14, 15.46] 10.64 [4.61, 17.66] 10.64 [4.61, 17.66] %	



using ultrasonography in children with and without constipation. The meta-analysis showed that the mean RD was significantly larger in children with constipation versus controls with high heterogeneity (MD, 10.35 mm; 95% CI, 6.97-13.74; P<0.001; I²=94%) (Fig. 2A).

Subgroup analyses across continents (America, Asia,

Africa, and Europe) revealed no significant differences in RD between children with and without constipation (P=0.27). Similarly, a subgroup analysis based on the conditions in the control group (healthy children, children with urological problems, and those with other issues) showed no significant variance in RD (P=0.95) (Fig. 2B).

132 Tran DL, et al. Transabdominal ultrasonography for diagnosing functional constipation in children

Meta-regression models examining the influence of mean age, weight, and height on RD in children demonstrated no significant association: mean age (coefficient, -0.022; 95% CI, -0.244 to 0.200; *P*=0.843), mean weight (coefficient, 0.011; 95% CI, -0.025 to 0.047; *P*=0.543), and mean height (coefficient, 0.025; 95% CI, -0.031 to 0.081; *P*=0.385) (Supplementary material 5).

A funnel plot analysis indicated a relatively symmetrical inverted shape (Supplementary material 6).

2) Anterior rectal wall thickness

Among the included studies, 3 (n=207) used ultrasonography to measure the anterior rectal wall thickness. The anterior rectal wall thickness was higher among constipated children than that of controls; however, this difference was not statistically significant. Additionally, there was high heterogeneity among studies (MD, 0.44; 95% CI, -0.26 to 1.13; P=0.22; I²=95%; random-effects model) (Fig. 3).

Funnel plot analysis indicated no inverted shape (Supplementary material 7).

3) Diagnostic value of RD for FC in children

Table 2 presents the RD cutoff points for diagnosing FC in children from specific studies. The analytical results are illustrated in Fig. 4, which shows the SROC curve for




Fig. 3. Forest-plot analysis of anterior rectal wall thickness in children. CI, confidence interval; SD, standard deviation; IV, inverse variance; *df*, degrees of freedom.




Fig. 4. Pooled analysis used to derive the optimal rectal diameter cutoff point on ultrasonography for diagnosing functional constipation in children: Youden index (A), study-specific receiver operating characteristic (ROC) curves (B), meta-analytic summary ROC (SROC) curve (C).

Table 2. Cutoff	point for diagnos	is of functional con	stipation in children

Study	Patients included in analysis	Cutoff point (mm)	True positive (cases)	False positive (cases)	True negative (cases)	False negative (cases)	Sensitivity (95% CI)	Specificity (95% CI)
Klijn et al. 2004 ²⁹⁾	49	28 ^{b)}	23	6	20	0	1	0.77 (0.61–0.93)
		33 ^{b)}	23	1	25	0	1	0.96 (0.88–1)
Singh et al. 2005 ¹⁷⁾	177	30	71	20	62	24	0.75 (0.66–0.83)	0.76 (0.66–0.85)
		40 ^{b)}	24	0	82	71	0.26 (0.17–0.34)	1
Joensson et al. 2008 ¹³⁾	49	3.68 ^{b)}	16	1	21	11	0.59 (0.4–0.77)	0.95 (0.87–1)
Karaman et al. 2010 ¹²⁾	66	24.4	25	7	24	10	0.71 (0.56–0.86)	0.76 (0.62–0.92)
Doniger et al. 2018 ¹⁴⁾	50	38	28	5	13	4	0.86 (0.69–0.96)	0.71 (0.53–0.85)
Hamdy et al. 2023 ³¹⁾	100	28	42	4	46	8	0.84 (0.74–0.94)	0.92 (0.84-0.99)
		30 ^{a)}	40	4	46	10	0.8 (0.68–0.91)	0.92 (0.84–0.99)

CI, confidence interval.

^{a)}Asked via email. ^{b)}Data extracted from a chart or box.

RD for the diagnosis of FC. This indicates that an optimal cutoff point for RD at 31 mm, when measured using ultrasonography, can diagnose constipation in children with good accuracy (AUC, 0.86; 95% CI, 0.80–0.91; *P*<0.001), sensitivity of 0.75 (95% CI, 0.59–0.86), and specificity of 0.84 (95% CI, 0.68–0.93).

Discussion

This meta-analysis showed a significantly larger RD measured using transabdominal ultrasonography among constipated children than controls, albeit with high heterogeneity among participants. An RD cutoff value of 31 mm demonstrated a good diagnostic value when Rome criteria were used as the diagnostic standard for FC. In contrast, anterior rectal wall thickness measured using the same method did not significantly differ between constipated children and controls across the pooled data.

The heterogeneity of the control group may have influenced the results of this meta-analysis. However, the subgroup analyses across continents consistently showed a larger RD in children with constipation, underscoring the robustness of this finding. Additionally, the larger RD in constipated children appeared to be independent of concurrent conditions observed in the control group, suggesting its utility as a diagnostic parameter for FC. This observation aligns with the pathophysiological mechanism of FC, particularly in younger children who exhibit withholding behavior, contributing to rectal dilation and potential megarectal development.^{18,19,35}

In 2014, the European Society for Pediatric Gastroenterology Hepatology and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition recommended transabdominal ultrasonography as a straightforward and noninvasive method for assessing FC in children. However, owing to limited data availability at the time, particularly with only 4 studies evaluating transabdominal ultrasonography, the standardization of measurement conditions and establishment of average values are lacking. Consequently, these organizations do not advocate for transabdominal ultrasonography as a diagnostic tool for FC.³⁶⁾

To date, numerous proposed RD cutoff values using transabdominal ultrasonography for diagnosing FC have been suggested,^{12-14,27,29,32,37)} with some studies indicating variations in children's age, weight, and height.^{12,17,30,38)} Despite conducting a meta-regression analysis to explore these variables, no statistically significant correlations with RD were found, likely due to the predominance of toddlers and young children in the analyzed data who were generally healthy or had minor illnesses unlikely to impact their growth parameters. Therefore, the cutoff threshold of 31 mm for RD can only be used for diagnosing FC in toddlers and young children and should be carefully applied to other age groups.

While this meta-regression analysis did not identify significant associations among age, height, weight, and RD, limitations in the collected data hindered further exploration of factors such as bladder volume, fecal incontinence, and duration of constipation symptoms.^{31,39} Future studies could benefit from investigating these aspects as well as evaluating alternative parameters such as the rectopelvic ratio proposed by Bijoś et al.³⁴⁾ for diagnosing FC in children.

Anterior rectal wall thickness is a proposed parameter for diagnosing FC. However, only 3 pooled studies have reported such measurements. Two studies conducted by Karaman et al.¹²⁾ and Pop et al.³⁰⁾ showed higher anterior rectal wall thicknesses in constipated children than healthy controls. Conversely, the study by Momeni et al.³²⁾ showed lower anterior rectal wall thicknesses in the constipated group than in children who underwent transabdominal ultrasonography for other reasons. An analysis of these studies indicated no significant relationship with FC, suggesting that it may not serve as a reliable diagnostic indicator for this condition. Similarly, while transabdominal ultrasonography shows promise for detecting fecal impaction,^{11,16,40)} its role in replacing DRE remains under review.

This meta-analysis has several limitations. First, we were unable to comprehensively investigate all potential factors influencing RD, including bladder filling, time of last defecation, fecal impaction, and duration of constipation symptoms, due to data restrictions from previous studies. Second, each study included in the pooled analysis had a relatively small sample size and exhibited heterogeneity. Third, most studies had a high RoB, mainly because of the lack of blinding in the RD evaluation. To enhance our understanding and refine the diagnostic utility of RD in constipated children, future research should prioritize larger cohorts and standardized methodologies. This approach would enable a more comprehensive exploration of the factors influencing RD, as well as anterior wall diameter and fecal content, thereby providing clearer insight into its diagnostic implications.

In conclusion, this meta-analysis demonstrated a statistically significant difference in RD measured using transabdominal ultrasonography between constipated and non-constipated children. Using a cutoff value of 31 mm, transabdominal ultrasonography exhibited good diagnostic accuracy for FC in children. Given its noninvasive, safe, and well-accepted nature among children, it can effectively assess RD, a parameter that can be integrated into the Rome diagnostic criteria for FC in children.

Footnotes

Supplementary materials: The supplementary materials 1-7 for this article is available at https://doi.org/10.3345/ cep.2024.00927.

Conflicts of interest: No potential conflict of interest relevant to this article was reported.

Funding: This research was supported by the Ratchadapisek Sompoch Endowment Fund (2023), Chulalongkorn University (Meta_66_007_3000_002) and Thailand Science Research and Innovation Fund Chulalongkorn University (HAE663000047).

Author contribution: Conceptualization: PSintusek, DLT; Data curation: DLT, PNTT, PSintusek; Formal analysis: DLT, NTP; Methodology: PSintusek, DLT, PSusantitaphong; Project administration: PP, PSusantitaphong; Writing original draft: PSintusek, DLT; Writing - review & editing: PSintusek, DLT

ORCID:

Duc Long Tran () https://orcid.org/0000-0002-2576-9209 Phu Nguyen Trong Tran () https://orcid.org/0000-0003-2936-8768

Paweena Susantitaphong D https://orcid.org/0000-0001-9813-9219

Phichayut Phinyo Dhttps://orcid.org/0000-0002-8543-6254 Palittiya Sintusek Dhttps://orcid.org/0000-0003-4441-0151

References

- 1. Benninga MA, Voskuijl WP, Taminiau JA. Childhood constipation: is there new light in the tunnel? J Pediatr Gastroenterol Nutr 2004;39:448-64.
- 2. Tran DL, Sintusek P. Functional constipation in children: what physicians should know. World J Gastroenterol 2023; 29:1261-88.
- 3. Ansari H, Ansari Z, Lim T, Hutson JM, Southwell BR. Factors relating to hospitalisation and economic burden of paediatric constipation in the state of Victoria, Australia, 2002-2009. J Paediatr Child Health 2014;50:993-9.
- 4. Liem O, Harman J, Benninga M, Kelleher K, Mousa H, Di Lorenzo C. Health utilization and cost impact of childhood constipation in the United States. J Pediatr 2009;154:258-62.
- 5. Vriesman MH, Rajindrajith S, Koppen IJN, van Etten-Jamaludin FS, van Dijk M, Devanarayana NM, et al. Quality of life in children with functional constipation: a systematic review and meta-analysis. J Pediatr 2019;214:141-50.
- 6. Benninga MA, Faure C, Hyman PE, St James Roberts I,

Schechter NL, Nurko S. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology 2016 Feb 15:S0016-5085(16)00182-7. doi: 10.1053/j.gastro.2016.02. 016. [Epub].

- 7. Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Childhood functional gastrointestinal disorders: child/ adolescent. Gastroenterology 2016;150:1456-68.
- 8. Poddar U, Singh S, Pawaria A, Srivastava A, Yachha SK. Aetiological spectrum, clinical differentiation and efficacy of polyethylene glycol over lactulose in children with constipation: EXPERIENce of 316 cases. J Paediatr Child Health 2019;55:162-7.
- 9. Makhwana VA, Acharyya K, Acharyya S. Profile of functional constipation in children at a referral hospital. Indian Pediatrics 2022;59:287-9.
- 10. Safder S, Rewalt M, Elitsur Y. Digital rectal examination and the primary care physicians: a lost art? Clin Pediatr (Phila) 2006;45:411-4.
- Berger MY, Tabbers MM, Kurver MJ, Boluyt N, Benninga MA. Value of abdominal radiography, colonic transit time, and rectal ultrasound scanning in the diagnosis of idio pathic constipation in children: a systematic review. J Pediatr 2012;161:44-50.e1-2.
- 12. Karaman A, Ramadan SU, Karaman I, Gokharman D, Erdogan D, Kacar M, et al. Diagnosis and follow-up in constipated children: should we use ultrasound? J Pediatr Surg 2010;45:1849-55.
- 13. Joensson IM, Siggaard C, Rittig S, Hagstroem S, Djurhuus JC. Transabdominal ultrasound of rectum as a diagnostic tool in childhood constipation. J Urol 2008;179:1997-2002.
- 14. Doniger SJ, Dessie A, Latronica C. Measuring the transrectal diameter on point-of-care ultrasound to diagnose constipation in children. Pediatr Emerg Care 2018;34:154-9.
- 15. Matsumoto M, Misawa N, Tsuda M, Manabe N, Kessoku T, Tamai N, et al. Expert consensus document: diagnosis for chronic constipation with faecal retention in the rectum using ultrasonography. Diagnostics 2022;12:300.
- Burgers R, de Jong TP, Benninga MA. Rectal examination in children: digital versus transabdominal ultrasound. J Urol 2013;190:667-72.
- 17. Singh SJ, Gibbons NJ, Vincent MV, Sithole J, Nwokoma NJ, Alagarswami KV. Use of pelvic ultrasound in the diagnosis of megarectum in children with constipation. J Pediatr Surg 2005;40:1941-4.
- Vriesman MH, Benninga MA. Functional constipation and fecal incontinence. Peadiatric sastrointestinal and liver diseases. Philadelphia (PA): Elsevier, 2021:106-18.
- Rial R, Uc A. Functional constipation. In: Kleinman RE, Goulet O-J, Mieli-Vergani G, Sanderson IR, Sherman PM, Shneider BL, editors. Walker's peadiatric gastrointestinal disease. New York: People's Medical Publishing House, 2018:991-1005.
- 20. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36.
- 21. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol

2014;14:135.

- 22. Steinhauser S, Schumacher M, Rucker G. Modelling multiple thresholds in meta-analysis of diagnostic test accuracy studies. BMC Med Res Methodol 2016;16:97.
- 23. Li F, He H. Assessing the accuracy of diagnostic tests. Shanghai Arch Psychiatry 2018;30:207-12.
- 24. Noma H, Matsushima Y, Ishii R. Confidence interval for the AUC of SROC curve and some related methods using bootstrap for meta-analysis of diagnostic accuracy studies. Commun Stat Case Stud Data Anal Appl 2021;7:344-58.
- 25. Gatzinsky C, Sillen U, Borg H, Bostrom H, Abrahamsson K, Sjostrom S. Transabdominal ultrasound of rectal diameter in healthy infants: a prospective cohort study during the first year of life. J Paediatr Child Health 2023;59:1021-7.
- 26. de Abreu GE, de Souza LA, Dourado ER, Schimitz AP, Veiga ML, Barroso U Jr. Role of transverse diameter of the rectum in lower urinary tract symptoms and functional constipation in children and adolescents. J Paediatr Child Health 2020;57:121-5.
- 27. Hatori R, Tomomasa T, Ishige T, Tatsuki M, Arakawa H. Fecal retention in childhood: Evaluation on ultrasonography. Pediatr Int 2017;59:462-6.
- 28. Burgers R, de Jong TP, Benninga MA. Rectal examination in children: digital versus transabdominal ultrasound. J Urol 2013;190:667-72.
- 29. Klijn AJ, Asselman M, Vijverberg MA, Dik P, de Jong TP. The diameter of the rectum on ultrasonography as a diagnostic tool for constipation in children with dysfunctional voiding. J Urol 2004;172(5 Pt 1):1986-8.
- 30. Pop D, Tătar S, Fufezan O, Farcău D. Rectum sizes: assessment by ultrasonography in children with functional constipation. J Paediatr Child Health 2021;57:1244-9.
- Hamdy AM, Sakr HM, Boules IS, Awad YMM. The role of rectal ultrasound in children with functional constipation. J Paediatr Child Health. 2023;59:533-6.
- 32. Momeni M, Momen-Gharibvand M, Kulouee N, Javaherizadeh H. Ultrasonography in determining the rectal diameter and rectal wall thickness in children with and without constipation: a case-control study. Arq Gastroenterol 2019;56:84-7.

- 33. Modin L, Dalby K, Walsted AM, Jakobsen M. Transabdominal ultrasound measurement of rectal diameter is dependent on time to defecation in constipated children. J Paediatr Child Health 2015;51:875-80.
- 34. Bijoś A, Czerwionka-Szaflarska M, Mazur A, Romañczuk W. The usefulness of ultrasound examination of the bowel as a method of assessment of functional chronic constipation in children. Pediatr Radiol 2007;37:1247-52.
- 35. Scott SM, van den Berg MM, Benninga MA. Rectal sensorimotor dysfunction in constipation. Best Pract Res Clin Gastroenterol 2011;25:103-18.
- 36. Tabbers MM, DiLorenzo C, Berger MY, Faure C, Langendam MW, Nurko S, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 2014;58:258-74.
- 37. Imanzadeh F, Hosseini A, Khalili M, Naghdi E, Hajipour M, Yazdanifard P, et al. Transabdominal ultrasound measurement of the diameter of rectal ampulla as a less invasive modality for digital rectal examination in children with functional constipation. Iran J Pediatr 2022;32:e114354.
- 38. Shapouri S, Matani R, Salahshoor A, Qorbani M, Hosseini A, Norouzi M, et al. Rectal measurements and their correlation with bowel habits: evaluation by trans-abdominal ultrasound in children with functional constipation. J Paediatr Child Health 2022;58:1792-6.
- 39. Lakshminarayanan B, Kufeji D, Clayden G. A new ultrasound scoring system for assessing the severity of constipation in children. Pediatr Surg Int 2008;24:1379-84.
- 40. Modin L, Walsted AM, Jakobsen MS. Identifying faecal impaction is important for ensuring the timely diagnosis of childhood functional constipation. Acta Paediatr 2015; 104:838-42.

How to cite this article: Tran DL, Tran PNT, Susantitaphong P, Phinyo P, Sintusek P. Value of transabdominal ultrasonography for diagnosing functional constipation in children: a systematic review and meta-analysis. Clin Exp Pediatr 2025;68:127-35.